Clinical Trial

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-05-12; most recent amendment 2024-04-07.
Status change: Active, Not Recruiting → Completed 2024-04-07
Status change: Recruiting → Active, Not Recruiting 2020-10-19
Trial Details
NCT Number NCT03154619
Lead Sponsor SerenaGroup, Inc.
Collaborators: TR Therapeutics
Conditions Venous Leg Ulcer
Enrollment 80 participants
Start Date 2016-11
Primary Completion 2019-04-04 (estimated)
Study Completion 2021-04-01 (estimated)
Updated on ClinicalTrials.gov 2020-10-22